LIDDS Liproca® Depot Phase IIb study results presented at EMUC19 showing both primary and secondary endpoints being met
UPPSALA, SWEDEN – LIDDS AB (publ) Phase IIb clinical data from the LPC-004 prostate cancer study on LIDDS Liproca® Depot were presented today in an oral session at the 11th European Multidisciplinary Congress on Urological Cancers, EMUC19. The study met both its primary and secondary endpoints as well as demonstrated that a larger proportion of intermediate risk patients, which is the Liproca Depot target group, are PSA responders. The presentation can be accessed through LIDDS webpage and are also attached to this release.
The phase IIb results from the LPC-004 prostate cancer study was presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019 by Professor Laurence Klotz, a world leading expert in Active Surveillance of prostate cancer patients. Professor Klotz was one of the LPC-004 study investigators and is Professor at the University of Toronto Division of Urology at the Sunnybrook Health Sciences Centre in Canada.
The preliminary data recently released from the phase IIb study, LPC-004, confirms that 90 % of patients receiving 16 ml intraprostatic injection of Liproca® Depot experienced a PSA reduction and also that 16 ml is the optimal dosage for future Phase III studies. Further, the study showed no systemic hormonal adverse reactions, that Liproca® Depot is safe and well tolerated by the patients, and that 84 % of patients being treated were amenable to a second injection of Liproca® Depot.
As LIDDS advances Liproca® Depot towards late-stage clinical development, LIDDS intends to target intermediate risk patients in its phase III trial. The LPC-004 study showed that a larger proportion of intermediate risk patients are PSA responders and that this group display a stronger mean PSA decrease compared to low risk patients.
– The results confirm that Liproca® Depot can offer a completely novel approach to complement active surveillance in intermediate risk prostate cancer patients. Liproca® Depot is well tolerated without the hormonal side effects associated with anti-androgen therapy, and is equally easy to administer as performing a prostate biopsy. Liproca® Depot treatment could contribute to the benefit of prostate cancer patients in the future, says Professor Laurence Klotz, a world leading expert and one of the study investigators and Professor at the University of Toronto Division of Urology.
– The results regarding the intermediate risk patients further validate the continued clinical development of Liproca® Depot. As announced recently, our licensing partner, Jiangxi Phuong, has decided to progress with the phase III trial in China and we will continue the commercial activities in order to sign further licensing agreements in other major markets, says Monica Wallter, CEO, LIDDS.
About the Phase IIb Liproca® Depot clinical trial
The single blind, two-part dose finding study aimed to determine the highest tolerable dose of Liproca® Depot in part I and to determine the level of PSA reduction for part II patients at month 5. The study was conducted at eight specialist urology clinics in Canada; Lithuania and Finland. The study involved 61 patients diagnosed with localized non-aggressive prostate cancer who were on Active Surveillance. Patients were followed for six months to assess response and tolerability. Three previous clinical trials (LPC-001, LPC-002 and LPC-003) involved a total of 57 patients and showed promising results for tolerability and effect on tumor tissue, prostate volume and the PSA biomarker.
About prostate cancer and the market
Of the 1.2 million men diagnosed with prostate cancer globally each year, about 420,000 are assessed as intermediate risk and placed on ‘Active Surveillance’ where they are monitored regularly. There is no standard drug treatment for these cancer patients and many treating doctors see an unmet need.
According to market research firm GlobalData, the global market for prostate cancer drugs is expected to grow to USD 8.3 billion annually by 2023. Liproca® Depot’s target group is an untapped market potentially exceeding USD 3 billion per year.
About Liproca® Depot and NanoZolid®
NanoZolid® is a safe, flexible and functional method of delivering drugs. When injected, NanoZolid® forms a solid depot releasing the active drug over periods of potentially more than six months. As it releases its drug load, the NanoZolid® depot dissolves and is absorbed harmlessly into the body.
Liproca® Depot combines NanoZolid® and 2-HOF (2-hydroxyflutamide), a well-established antiprostate cancer drug. Liproca® Depot’s target group is patients under Active Surveillance (AS) with intermediate risk of cancer progression.
For additional information, please contact:
Monica Wallter, CEO, LIDDS +46 (0)737 07 09 22 firstname.lastname@example.org
This information is such that LIDDS AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, at 10:10 CET on November 16, 2019.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, email@example.com, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
SERSTECH AB: Serstech receives EU funding for CBRN project14.8.2020 12:00:00 CEST | Press release
A consortium of public and private organizations, of which Serstech is part, has been granted funding from the European Commission. The project aims to develop technologies, based on Raman and SERS (Surface Enhanced Raman Spectroscopy), to detect and identify chemical warfare agents and toxic industrial compounds in liquid and gas form. Serstech will supply modified Raman devices as part of the project. In August, Serstech will receive the initial payment of approximately 2 MSEK and will receive another 2 MSEK over the project period, which extends over three and a half years. The consortium includes several European universities and the Swedish Defence Research Agency (FOI). The project aims to provide a solution for first responders and CBRN (Chemical, Biological, Radiological, Nuclear) specialists to detect hazards in their everyday work. The solution will use Raman technology from Serstech and include both mobile and fixed detection capabilities. Important success factors in the pr
Transfer of Aspo Plc treasury shares14.8.2020 12:00:00 CEST | Press release
Aspo Plc Stock Exchange Release August 14, 2020 at 13 p.m. Transfer of Aspo Plc treasury shares Aspo Plc has transferred 5,000 treasury shares on the basis of the Restricted Share Plan 2020. The transfer is based on the authorization given by the Annual Shareholders’ Meeting on May 4, 2020. The shares have been transferred according to the terms of Restricted Share Plan 2020 without compensation. After the transfer, Aspo Plc holds a total of 161 650 treasury shares. Aspo announced the Restricted Share Plan 2020 in a stock exchange release issued on June 18, 2020. ASPO PLC Aki Ojanen CEO For further information, please contact: Aki Ojanen, CEO Aspo Plc, +358 400 106 592, firstname.lastname@example.org DISTRIBUTION: Nasdaq Helsinki Key media www.aspo.com Aspo is a conglomerate that owns and develops business operations in Northern Europe and growth markets, focusing on demanding B2B customers. The aim of our strong corporate brands – ESL Shipping, Leipurin and Telko– is to be the market leaders in
RESULT OF SEK TENDER OPERATION FOR ONWARD LENDING14.8.2020 11:30:00 CEST | Press release
RESULT OF SEK TENDER OPERATION FOR ONWARD LENDING AUG-14-2020Auction date:AUG-14-2020Settlement date:AUG-18-2020Final repayment date:AUG-19-2024Offered volume:SEK 50 billionTotal bid amount:SEK 0.0 billionNumber of bids 0 Allotment:SEK 0.0 billionInterest rate: 0.00 %
Conference call 24 August at 08.30 (CET) about Interim Report H1 202014.8.2020 10:44:37 CEST | Press release
14/08/2020 COMPANY ANNOUNCEMENT 9/2020 Goodvalley will release its Interim Report H1 2020 on 21 August 2020. On 24 August 2020 at 08.30 (CET), Goodvalley will host a conference call at which CEO Hans Henrik Pedersen and Vice CEO Kristian Brokop Jacobsen will provide comments on financial and operational performance, the outlook and answer questions. Registration is not required. The conference call will be conducted in English and can be followed live here: https://edge.media-server.com/mmc/p/y95a4frp Participants should dial the numbers provided below and state conference code 6680528 Denmark:+45 32 72 80 42Norway:+47 239 60264Sweden:+46 (0)850 692180Poland+48 222 120 152United Kingdom:+44 (0)844 571 8892United States:+1 631 5107495 Further Information Group CFO, Jakob Brasted + 45 76 52 20 00 email@example.com Goodvalley at a glance Goodvalley is an international producer of high-quality pork products operating in Poland, Ukraine and Russia based on Danish production standards. The
Mandalay Resources Corporation tillkännager resultatrapporten för andra kvartalet 202014.8.2020 10:24:01 CEST | Pressemelding
TORONTO, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) tillkännagav idag resultatrapporten för kvartalet som slutade den 30 juni 2020. Bolagets sammanfattade och konsoliderade delårsrapporter för kvartalet som slutade den 30 juni 2020, tillsammans med ledningens diskussion och analys (”MD&A”) för motsvarande period, finns tillgängliga under bolagets profil på www.sedar.com och på bolagets webbplats www.mandalayresources.com. Alla valutor i detta pressmeddelande avser US-dollar om inget annat är angivet. Under det andra kvartalet 2020 genererade bolaget intäkter på 42,3 miljoner USD, en justerad EBITDA på 21,3 miljoner USD och en konsoliderad nettovinst på 7,6 miljoner USD eller 0,08 USD per aktie. Dominic Duffy, President och Chief Executive Officer för Mandalay, kommenterar resultaten, ”Mandalays starka finansiella resultat för andra kvartalet drevs av ännu en rekordstor kvartalsjusterad EBITDA vid Costerfield på
Disclosure through the National Storage Mechanism14.8.2020 10:14:41 CEST | Press release
14 August 2020 Disclosure through the National Storage Mechanism Pursuant to the Listing Rules LR 14.3.11AR to LR 14.3.11DR approved by the Financial Conduct Authority of the United Kingdom, Public Joint Stock Company Acron (Moscow Exchange and LSE: AKRN) uploaded to the National Storage Mechanism the Prospectus for Global Depositary Receipts of Joint Stock Company Acron listed at the London Stock Exchange since 2008, and Acron’s Charter as amended. Mediacontacts: Sergey Dorofeev Anastasiya Gromova Tatiana Smirnova Public Relations Phone: +7 (495) 777-08-65 (ext. 5196) Investor contacts: Ilya Popov Investor Relations Phone: +7 (495) 745-77-45 (ext. 5252) Background Information Acron Group is a leading vertically integrated mineral fertiliser producer in Russia and globally, with chemical production facilities in Veliky Novgorod (Acron) and Smolensk region (Dorogobuzh). The Group owns and operates a phosphate mine in Murmansk region (North-Western Phosphorous Company, NWPC) and is imple